The article discusses the work of Noetik, a company founded by Ron Alfa, which is leveraging AI to improve cancer treatment through better cohort selection for clinical trials. Here are some key points:
Background:
- Ron Alfa's Thesis: Many treatments that appear to fail in clinical trials actually do work but on specific patient subgroups with unique tumor biologies.
- Data Collection: Noetik spent almost two years collecting extensive data from real human tumors, including multimodal datasets such as spatial transcriptomics and proteomics.
Technology:
- Virtual Cell Model: Using self-supervised learning, Noetik has created a model that can simulate how patients will respond to experimental treatments.
- Data Scale: The company has collected hundreds of millions of images from thousands of human tumors, creating detailed maps of the cell makeup in local environments.
Applications:
- Cohort Selection: By identifying which subgroups of patients are likely to respond positively to specific treatments, Noetik aims to improve clinical trial success rates.
- Drug Discovery: The models can guide drug discovery towards more promising candidates that have a higher likelihood of making it through clinical trials.
Partnership with GSK:
- GSK's Interest: Gl
Read the full article at Latent Space
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
6
Contents
alinemati1983-6987Written by alinemati1983-6987
![[AINews] The Unreasonable Effectiveness of Closing the Loop](/_next/image?url=https%3A%2F%2Fmedia.nemati.ai%2Fmedia%2Fblog%2Fimages%2Farticles%2F600e22851bc7453b.webp&w=3840&q=75)
